Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Bank of America Securities 2025 Healthcare Conference. The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a fireside chat on May 13, 2025, at 6:00 p.m. ET / 3:00 p.m. PT. Investors can access a live audio webcast of the presentation through Kura's website, with a replay available afterward.
Kura Oncology (KURA) has initiated dosing in KOMET-015, a Phase 1 clinical trial evaluating ziftomenib in combination with imatinib for patients with advanced gastrointestinal stromal tumors (GIST) who failed imatinib treatment. The trial aims to assess safety, tolerability, and preliminary antitumor activity.
Preclinical studies showed the combination demonstrates robust antitumor activity in both imatinib-sensitive and resistant GIST models through a synthetic lethal mechanism. With 4,000-6,000 new GIST cases diagnosed annually in the U.S. and 60% of patients developing imatinib resistance within two years, ziftomenib could potentially delay or overcome this resistance.
The KOMET-015 Phase 1a/1b trial will evaluate safety, determine recommended Phase 2 dosing, and measure endpoints including clinical benefit, overall response rate, progression-free survival, and overall survival. This marks the first clinical trial combining a menin inhibitor with standard GIST treatments.
Kura Oncology (KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. market close on Thursday, May 1, 2025.
Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss financial performance and provide a corporate update. Investors can access the live call via phone using the numbers (800) 245-3047 (domestic) or (203) 518-9765 (international) with conference ID: KURAQ1. A live webcast and replay will be available through the investor relations section of Kura's website.
Kura Oncology (KURA) and Kyowa Kirin have submitted a New Drug Application (NDA) to the FDA for ziftomenib, their oral menin inhibitor designed to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutation.
The submission was completed on March 31, 2025, with FDA expected to determine application completeness within 60 days. Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The company has requested Priority Review, which could result in a six-month FDA review period if granted.
This therapeutic candidate represents a potential first FDA-approved targeted therapy for NPM1-mutant AML patients, addressing an significant unmet medical need in this devastating disease.
Kura Oncology (NASDAQ: KURA) has announced the granting of inducement awards to four new employees as approved by the Company's Compensation Committee on April 1, 2025. The awards consist of nonstatutory stock options to purchase 79,500 shares of common stock under the Company's 2023 Inducement Option Plan.
The stock options have an exercise price of $6.38 per share, matching Kura's closing sales price on April 1, 2025. The vesting schedule spans four years, with 25% of shares vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.
Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum.
The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a virtual fireside chat scheduled for April 8, 2025, at 10:30 a.m. ET / 7:30 a.m. PT. Investors and interested parties can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.
Kura Oncology (NASDAQ: KURA) announced that preclinical data for its next-generation farnesyl transferase inhibitor (FTI) KO-2806 has been selected for oral presentation at the 2025 AACR Annual Meeting in Chicago.
The presentation will focus on KO-2806's combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell carcinoma (ccRCC). The oral presentation, titled 'Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents,' is scheduled for April 28, 2025.
The company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 both as monotherapy and in combination with cabozantinib for RCC treatment in the second half of 2025.
Kura Oncology (KURA) has announced the granting of inducement awards to six new employees as approved by the Company's Compensation Committee on March 3, 2025. The awards consist of nonstatutory stock options to purchase 190,000 shares of common stock under the Company's 2023 Inducement Option Plan.
The stock options were granted at an exercise price of $7.25 per share, matching the Company's closing sales price on March 3, 2025. The vesting schedule spans four years, with 25% of shares vesting after the first year, followed by monthly vesting of the remaining shares over 36 months, contingent on continued employment.